Mr. Hardaway joins the firm to assist the Growth Buyout team with identifying and executing opportunities in the post-acute sector.
Mr. Hardaway joined Frazier Healthcare partners as a member of the Growth Buyout team in 2016.
Mr. Hardaway most recently served as CEO of Millennium Health, the nation’s largest specialty, clinical toxicology lab. In addition to clinical toxicology and under Mr. Hardaway’s leadership, the company developed a suite of genetic testing and predictive analytic products that armed healthcare providers with medication intelligence in an effort to improve medication effectiveness. Mr. Hardaway served on the board of Millennium Health and while in San Diego was also on the board of Big Brothers Big Sisters of San Diego, where he launched a highly successful STEM program in conjunction with Millennium Health.
Mr. Hardaway has also spent more than 23 years in various leadership and senior executive roles in the post-acute sector. As Executive Vice President at Kindred Healthcare, he had leadership responsibility for more than 60 specialty and rehab hospitals across the U.S. and managed well over $1 billion in annual revenue. Prior to the acquisition of RehabCare by Kindred, Mr. Hardaway was President of the Hospital Division at RehabCare where he led the day-to-day operations of the RehabCare specialty hospitals nationwide. Before joining RehabCare/Kindred, he was the President & COO of Triumph Healthcare, a Houston-based specialty Hospital Company. Under Mr. Hardaway's leadership, Triumph grew from a small, single market player to being a national, highly regarded company that was later sold to RehabCare. Mr. Hardaway also held leadership roles with Select Medical Corporation, and started his successful career in the post-acute arena with Vencor. Early on, he worked in various aspects of healthcare consulting and gained valuable health plan experience during his time with Blue Cross Blue Shield of Texas.